Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CXD101 Given Orally (Twice Daily Dosing for 5 Consecutive Days in a 21-day Period) in Patients With Advanced Malignancies Expressing the Biomarker HR23B

X
Trial Profile

Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CXD101 Given Orally (Twice Daily Dosing for 5 Consecutive Days in a 21-day Period) in Patients With Advanced Malignancies Expressing the Biomarker HR23B

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 19 Oct 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zabinostat (Primary)
  • Indications Advanced breast cancer; Cervical cancer; Colorectal cancer; Diffuse large B cell lymphoma; Endometrial cancer; Follicular lymphoma; Head and neck cancer; Hodgkin's disease; Lung cancer; Lymphoma; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Peripheral T-cell lymphoma; Solid tumours; T-cell lymphoma; Waldenstrom's macroglobulinaemia
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 17 Oct 2022 Status changed from active, no longer recruiting to completed.
    • 07 Apr 2022 2-year survival of cancer patient treated with zabadinostat monotherapy results published in the Celleron Therapeutics Media Release
    • 06 Jan 2022 Planned End Date changed from 31 Dec 2021 to 31 Dec 2022.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top